Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 286-292

  Finkelstein, Steven E ^a   Grigsby, Perry W ^a,c   Siegel, Barry A ^b,c   Dehdashti, Farrokh ^b,c   Moley, Jeffrey F ^a,c   Hall, Bruce L ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

131I Scintigraphy; FDG PET; FDG PET CT; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CYST; DISEASE COURSE; FEMALE; HUMAN; INFUNDIBULAR CYST; INTERVERTEBRAL DISK DEGENERATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAPILLARY CARCINOMA; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUPRACLAVICULAR CYST; THYROID CANCER; DECISION MAKING; LABORATORY DIAGNOSIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE; WHOLE BODY IMAGING;

DECISION MAKING; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 38049180784     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9611-5     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:722-7
3. Grigsby PW, Baglan K, Siegel BA. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999;85:945-51
4. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med 2004;45:567-70
5. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981;71:806-14
6. 131I scanning in the management of treated differentiated thyroid carcinoma. Aust NZ J Med 1982;12:248-54
7. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7
8. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988;29:1790-4
9. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92
10. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112-21
11. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8
12. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797-804
13. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52
14. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302
15. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative value of 18F fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11
16. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001;42:1464-9
17. 131I scan. J Nucl Med 2001;42:71-6
18. 18F]-2-fluoro-2- deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003;149:293-300
19. 18F-FDG γPET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 2003;24:959-61
20. 131)I whole-body scans. Eur J Nucl Med Mol Imaging 2004;31:330-41
21. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115:237-43
22. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24
23. 18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006;12:152-8
24. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 2006;47:1260-6
25. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128:178-84
26. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48:221-6
27. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993;186:27-35
28. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234:879-85
29. Heller MT, Meltzer CC, Fukui MB, et al. Superphysiologic FDG uptake in the non-paralyzed vocal cord. Resolution of a false-positive PET result with combined PET-CT imaging. Clin Positron Imaging 2000;3:207-11
30. Lee M, Ramaswamy MR, Lilien DL, Nathan CO. Unilateral vocal cord paralysis causes contralateral false-positive positron emission tomography scans of the larynx. Ann Otol Rhinol Laryngol 2005;114:202-6
31. Gross ND, Weissman JL, Talbot JM, Andersen PE, Wax MK, Cohen JI. MRI detection of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope 2001;111:1905-9
32. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7
33. Medicare Coverage Database. Centers for Medicare & Medicaid Services, Baltimore. www.cms.hhs.gov/mcd/viewtechassess.asp?where=search&tid= 7&basket=ta:7: Systematic+Review+Of+Positron+Emission+Tomography+For+Follow%2DUp+Of+Treated+ Thyroid+Cancer (2007). Accessed on 5 June 2007